Annexon (ANNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
The annual meeting is scheduled for June 11, 2026, to be held virtually, with voting on four key proposals and director elections.
Only stockholders of record as of April 13, 2026, are eligible to vote, with 162,507,278 shares outstanding.
The Board recommends voting in favor of all proposals, including director elections, auditor ratification, executive compensation, and an amendment to increase authorized shares.
Voting matters and shareholder proposals
Four proposals: election of two Class III directors, ratification of KPMG LLP as auditor, advisory approval of executive compensation, and amendment to increase authorized shares from 300M to 500M.
Board recommends voting “For” all proposals.
Shareholders may submit proposals for the 2027 meeting between February 11 and March 13, 2027.
Board of directors and corporate governance
Board consists of eight members, with a majority deemed independent under Nasdaq rules.
Chair and CEO roles are separated; current chair is Thomas G. Wiggans, who will retire at the 2026 meeting.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.
Board diversity emphasized, with 56% female employees and 24% from diverse backgrounds as of March 2026.
Latest events from Annexon
- Pivotal data and regulatory filings in GBS, GA, and ANX1502 expected to drive major milestones in 2026.ANNX
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Late-stage pipeline advances and strong cash position support multiple 2026 milestones.ANNX
Q4 202530 Mar 2026 - Phase 3 trial for C1q inhibition in GA is fully enrolled, with pivotal results due Q4 2026.ANNX
KOL event20 Mar 2026 - Late-stage neuroinflammatory pipeline poised for major clinical and commercial milestones.ANNX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - ANX005 30 mg/kg met key efficacy and safety endpoints in GBS, advancing toward FDA submission.ANNX
Study Update31 Jan 2026 - Phase III GBS and GA data show strong efficacy, with regulatory and commercial momentum building.ANNX
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Phase III GBS data show rapid, durable efficacy, with key regulatory and pipeline milestones ahead.ANNX
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Pivotal 2026 catalysts for late-stage neuroinflammatory disease therapies with blockbuster potential.ANNX
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Positive GBS Phase III, oral therapy progress, and global GA trial highlight strong pipeline.ANNX
Jefferies London Healthcare Conference 202413 Jan 2026